Table of Contents
Lung Cancer International
Volume 2015, Article ID 317868, 6 pages
Research Article

Chemotherapy Treatment of Elderly Patients (≥70 Years) with Non-Small Cell Lung Cancer: A Seven-Year Retrospective Study of Real-Life Clinical Practice at Karolinska University Hospital, Sweden

1Department of Respiratory Medicine, Gävle Hospital, 80187 Gävle, Sweden
2Karolinska Institutet, Stockholm, Sweden
3Centre for Research and Development, Uppsala University, County Council of Gävleborg, Gävle, Sweden
4Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Solna, Stockholm, Sweden

Received 30 April 2015; Revised 25 June 2015; Accepted 28 June 2015

Academic Editor: Giovanni Luca Ceresoli

Copyright © 2015 Hirsh Koyi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


An increasing proportion of cancer patients are aged >65 years and many are aged >70 years. Treatment of the elderly with lung cancer has, therefore, become an important issue; so we performed a retrospective study of our patients to demonstrate how elderly patients with NSCLC are treated in real-life, clinical practice. All patients aged ≥70 years with NSCLC at our department were reviewed retrospectively. In total, 1059 patients (50.8% of all NSCLC patients). Of these patients, 243 (22.9%) received chemotherapy, 164 (70.4%) of whom were treated with a platinum doublet using carboplatin. Second- and third-line chemotherapy were given to 31.4% and 13.9% of patients, respectively. Median overall survival was 289 and 320 days for male and female patients, respectively. Patients with performance status (PS) 0 experienced significantly better survival than patients with PS1 or PS 2: 410, 314, and 204 days, respectively. Age was of less importance, with patients aged 70–79 years versus those aged ≥80 years. Treatment of elderly NSCLC patients with chemotherapy is feasible if they have a good PS and appears to prolong survival. In this study, we found no significant differences in survival either between age groups or genders.